Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Stephan

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe, , Fumiyo Nakagawa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 11, 2020
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort SettingLauren Greenberg, Lene Ryom, Gilles Wandeler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 12, 2018
Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral TherapyLuuk Gras, Margaret May, Lars Peter Ryder, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2023
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort StudyHortensia Álvarez, Amanda Mocroft, Lene Ryom, et al.
Plos One|December 31, 2020
Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortiumBastian Neesgaard, Amanda Mocroft, Robert Zangerle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2020
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency VirusLauren Greenberg, Lene Ryom, Bastian Neesgaard, et al.
The Lancet. HIV|September 23, 2021
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortiumLoveleen Bansi-Matharu, Andrew Phillips, Cristiana Oprea, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 11, 2024
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 25, 2014
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recoveryFrederik N Engsig, Robert Zangerle, Olga Katsarou, et al.
Emerging Infectious Diseases|February 21, 2018
New Lineage of Lassa Virus, Togo, 2016Shannon L M Whitmer, Thomas Strecker, Daniel Cadar, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe, , Fumiyo Nakagawa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 11, 2020
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort SettingLauren Greenberg, Lene Ryom, Gilles Wandeler, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 12, 2018
Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral TherapyLuuk Gras, Margaret May, Lars Peter Ryder, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2023
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort StudyHortensia Álvarez, Amanda Mocroft, Lene Ryom, et al.
Plos One|December 31, 2020
Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortiumBastian Neesgaard, Amanda Mocroft, Robert Zangerle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2020
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency VirusLauren Greenberg, Lene Ryom, Bastian Neesgaard, et al.
The Lancet. HIV|September 23, 2021
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortiumLoveleen Bansi-Matharu, Andrew Phillips, Cristiana Oprea, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 11, 2024
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 25, 2014
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recoveryFrederik N Engsig, Robert Zangerle, Olga Katsarou, et al.
Emerging Infectious Diseases|February 21, 2018
New Lineage of Lassa Virus, Togo, 2016Shannon L M Whitmer, Thomas Strecker, Daniel Cadar, et al.
Pageof 15